DiarioFarma. Biogen, a company that until now was characterized by the research, development, production and marketing of innovative medicines, mainly through the use of biotechnology, has launched its first two biosimilars on the Spanish market (Benepali and Flixabi, whose reference products are etanercept, from Pfizer, and Remicade, from MSD, respectively), the result of the joint venture started in 2013 with the Korean company Samsumg Bioepis. The objective, as indicated by the director of Biogen Biosimilares for Spain and Portugal, Ramón Villamarín, is to turn the company into 'a partner to contain the growing health expenditure and expand access to the greatest number of patients of biological medicines'.

READ MORE